G6PD was discovered and biochemically characterized in 1932 by Otto Warburg and Walter
Christian 1 in yeast and in red cells as an enzyme with a redox function. It was one of the first …

The gravity of the threat posed by vivax malaria to public health has been poorly
appreciated. The widely held misperception of Plasmodium vivax as being relatively …

Background Clinical effectiveness of previous regimens to treat Plasmodium vivax infection
have been hampered by compliance. We aimed to assess the dose–response, safety, and …

G6PD was discovered and biochemically characterized in 1932 by Otto Warburg and Walter
Christian 1 in yeast and in red cells as an enzyme with a redox function. It was one of the first …

Tafenoquine is a newly licensed antimalarial drug for the radical cure of Plasmodium vivax
malaria. The mechanism of action and optimal dosing are uncertain. We pooled individual …

The technical genesis and practice of 8-aminoquinoline therapy of latent malaria offer
singular scientific, clinical, and public health insights. The 8-aminoquinolines brought …

Introduction: Relapses are important contributors to illness and morbidity in Plasmodium
vivax and P. ovale infections. Relapse prevention (radical cure) with primaquine is required …

Primaquine was officially licensed as an anti-malarial drug by the FDA in 1952. It has
remained the only FDA licensed drug capable of clearing the intra-hepatic schizonts and …

Tafenoquine is an 8-aminoquinoline under investigation for the prevention of relapse in
Plasmodium vivax malaria. This open-label, dose-escalation study assessed quantitatively …

Malaria has been a human health concern ever since the dawn of mankind, but despite the
huge struggles made to date to fight this infection, in 2012 over half a million people were …